Prognostic factors related to overall survival in adolescent and young adults with medulloblastoma: A systematic review
- PMID: 35669013
- PMCID: PMC9161716
- DOI: 10.1093/noajnl/vdac016
Prognostic factors related to overall survival in adolescent and young adults with medulloblastoma: A systematic review
Abstract
Background: Medulloblastoma is a rare diagnosis among adolescents and young adults (AYA). Though prognostic factors and treatment are well characterized among children with medulloblastoma, equivalent data for AYA are sparse. We conducted a systematic review to identify predictors of survival among AYA with medulloblastoma.
Methods: We searched for primary studies of AYA (age 15-39 at diagnosis) with medulloblastoma in high-income countries within OVID MEDLINE, EMBASE, and EBM Reviews-Cochrane library databases from inception to August 2020. Patient demographics, primary outcomes, and univariate and multivariable data on all prognostic factors were collected from included studies. Prognosticators were characterized as patient, disease, or treatment-related.
Results: We identified 18 articles. 5-year overall survival ranged between 40% and 89%, while disease-free survival ranged from 49% to 89%. Study quality was low as assessed by the Quality in Prognostic factor Studies tool. Though meta-analyses were not possible due heterogeneity, narrative summaries suggested that lower disease burden, superior postoperative functional status, and higher doses and larger fields of radiation were associated with improved survival. Reported chemotherapy regimens were heterogeneous in timing, agents, and relationship with radiation, precluding meaningful comparisons. Only one study included molecular subgroups for analysis, with the majority (76.5%) of tumors classified as Sonic Hedgehog (SHH).
Conclusions: Prognostication and treatment of AYA medulloblastoma is limited by a dearth of primary evidence and lack of specificity for patients aged 15-39. Dedicated prospective trials to delineate the benefit of various chemotherapy and radiation regimens are required in this population to identify prognosticators and ideal treatment regimens.
Keywords: adolescent; medulloblastoma; prognosis; systematic review; young adults.
© The Author(s) 2022. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.
Figures
Similar articles
-
Medulloblastoma in China: clinicopathologic analyses of SHH, WNT, and non-SHH/WNT molecular subgroups reveal different therapeutic responses to adjuvant chemotherapy.PLoS One. 2014 Jun 16;9(6):e99490. doi: 10.1371/journal.pone.0099490. eCollection 2014. PLoS One. 2014. PMID: 24932704 Free PMC article.
-
Exclusive Hyperfractionated Radiation Therapy and Reduced Boost Volume for Standard-Risk Medulloblastoma: Pooled Analysis of the 2 French Multicentric Studies MSFOP98 and MSFOP 2007 and Correlation With Molecular Subgroups.Int J Radiat Oncol Biol Phys. 2020 Dec 1;108(5):1204-1217. doi: 10.1016/j.ijrobp.2020.07.2324. Epub 2020 Aug 6. Int J Radiat Oncol Biol Phys. 2020. PMID: 32768563
-
Treatment of Medulloblastoma in the Adolescent and Young Adult Population: A Systematic Review.J Adolesc Young Adult Oncol. 2025 Feb;14(1):18-32. doi: 10.1089/jayao.2024.0044. Epub 2024 Aug 23. J Adolesc Young Adult Oncol. 2025. PMID: 39178158
-
Adolescent and young adult glioma: systematic review of demographic, disease, and treatment influences on survival.Neurooncol Adv. 2022 Oct 22;4(1):vdac168. doi: 10.1093/noajnl/vdac168. eCollection 2022 Jan-Dec. Neurooncol Adv. 2022. PMID: 36479061 Free PMC article.
-
Current medulloblastoma subgroup specific clinical trials.Transl Pediatr. 2020 Apr;9(2):157-162. doi: 10.21037/tp.2020.03.03. Transl Pediatr. 2020. PMID: 32477916 Free PMC article. Review.
Cited by
-
Tumor-associated astrocytes promote tumor progression of Sonic Hedgehog medulloblastoma by secreting lipocalin-2.Brain Pathol. 2024 Jan;34(1):e13212. doi: 10.1111/bpa.13212. Epub 2023 Sep 18. Brain Pathol. 2024. PMID: 37721122 Free PMC article.
-
Review of 20 years of adult medulloblastoma treatment: Chemotherapy prescription trends and survival.Neurooncol Pract. 2022 Sep 18;10(2):186-194. doi: 10.1093/nop/npac074. eCollection 2023 Apr. Neurooncol Pract. 2022. PMID: 36970168 Free PMC article.
References
-
- Smoll NR. Relative survival of childhood and adult medulloblastomas and primitive neuroectodermal tumors (PNETs). Cancer. 2012; 118(5):1313–1322. - PubMed
-
- National Comprehensive Cancer Network. Central Nervous System Cancers. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines Version 5.2020), 2021; https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf. Accessed April 30, 2021. - PubMed
-
- Rutkowski S, von Hoff K, Emser A, et al. . Survival and prognostic factors of early childhood medulloblastoma: an international meta-analysis. J Clin Oncol. 2010; 28(33):4961–4968. - PubMed
Publication types
LinkOut - more resources
Full Text Sources